Author: Calcalist (Israel) Posted October 2, 2013
Israeli company IceCure Medical Inc., which is active in the market of medical instrumentation for women's health care, announced today [Sept. 30] a deal worth $100,000 for the sale in Japan of two systems developed by the company based on its IceSense3 system. The systems were sold for a first-of-its-kind use in a clinical trial designed to study [their effectiveness in] the destruction of cancerous lung tumors, to be held at the Kameda Medical Center, located in Kamogawa City in Japan. The system is used for treating breast cancer in the framework of clinical research conducted at the Kameda Medical Center.
Upon completion of the clinical trial and after analyzing its results, the company will reconsider the extent and duration of its future involvement in the treatment of lung cancer using extremely cold temperatures [a freezing method designed to destroy targeted cancerous tumors].
The clinical trial will be conducted by Dr. Akihiko Takahashi, head of chest surgery at the Kameda Medical Center. This comes after a preliminary trial on animals showed the IceCure Medical system to be more effective for treating cancerous lung tumors than other systems using extremely cold temperatures previously tested by Kameda physicians. The clinical trial is fully financed by the medical center.
The IceSense3 is a product for the treatment of fibroadenoma breast tumors. It consists of a closed-circle system that injects liquid nitrogen [into the tumor] through a unique needle developed by the company. It thus destroys benign breast tumors using extremely cold temperatures without damaging the healthy tissues surrounding the tumor.
Fibroadenomas are the most common type of benign breast tumor. It is a solid tumor common among women of various ages, with especially high prevalence among young women up to the age of 30. The size of a fibroadenoma breast tumor usually ranges from 1 to 3 centimeters, and it tends to increase during pregnancy and breastfeeding. The IceSense3 has been approved by the US Food and Drug Administration for marketing and sale in the United States, and it has also received the CE approval mark for marketing and sale in Europe.
According to studies conducted in the United States, lung cancer is the major mortality cause in the population, causing more deaths than all other most common types of cancer (colon, breast and prostate) taken together. These studies predict that about 228,000 new cases of lung cancer will be diagnosed in 2013 in the United States alone, and that the subsequent mortality rate will reach approximately 160,000, accounting for 27% of deaths due to cancer.
Read More: http://www.al-monitor.com/pulse/business/2013/10/icecure-medical-japan-kameda-medical-center-cancer.html